Aging Initiative at Harvard

@doclattermann Sign up now! luma.com/kb5j2ce5

Join us on February 28th for the Osteoarthritis Surgical Innovation and Science (OASIS) Symposium to hear from leading figures in osteoarthritis research, treatment, and biotechnology!

@doclattermann We are proud to announce a new speaker: Dr. Christian Lattermann @doclattermann, President of the International Cartilage Repair and Joint Restoration Society and Director of Research at Mass General Brigham Sports Medicine.

Register now here - spots are limited and filling fast: luma.com/6sbgpldh

Speaker event with genomics and metabolic disease expert Professor Melina Claussnitzer on 2/26/2026, 4-5pm! Learn how big data and human genetics fuels discovery of new targets for obesity, diabetes, and other population-scale cardiometabolic diseases.

Super excited to share that the @aginginit is hosting an event focused on osteoarthritis biology, surgery, and therapeutics. Despite almost 1B people projected to have OA by 2050, there are no approved disease-modifying therapies, pointing to the pressing need and opportunity for innovation. Registrations have just opened! luma.com/kb5j2ce5

Thank you again to Dr Bhasin and the Boston Pepper Center for helping move this field forward!

We recently hosted Dr. Shalender Bhasin for a workshop on clinical trials for function-promoting medicines. Key ideas included targeting real mobility issues, using patient-reported outcomes, pairing drugs with functional exercise, and using actigraphy to track daily gains.

Last Thursday, our COO and co-founder @eric_k_morgen , MD spoke at the Massachusetts State House, advocating for a fundamental shift in how we approach age-related disease. 80% of adults over 65 live with at least one chronic condition, driving over $500 billion in annual healthcare costs. But how do we translate advances in the science of longevity into treatments that improve quality of life for older adults living with multiple chronic diseases? At BioAge, we're answering this question by analyzing the world's most comprehensive human aging datasets—50+ million molecular data points spanning over 50 years—to identify therapeutic targets that address root causes of metabolic disease. Our advancing clinical programs, along with multiple pharma collaborations, demonstrate how human aging biology can inform drug discovery. Massachusetts —along with the other great states investing in innovation — has an opportunity to take the lead in aging biology research. State-level life sciences funding initiatives could accelerate the translation of aging science into therapeutics that extend healthy lifespan and reduce the burden of chronic disease. Grateful to the @aginginit and the MA Joint Committee on Aging and Independence for organizing this briefing and creating the space for science, policy, and patient impact to converge.

@eric_k_morgen @bioagelabs @RaianyRomanni @AFARorg We look forward to continuing our work to educate partners across all domains about the importance of aging biology research and biotechnology. From innovation, to community building, public support, and everything in between, we’re excited about the months ahead, stay tuned!

Many thanks to Dr. William Mair (Harvard), Dr. Eric Morgen @eric_k_morgen (@bioagelabs ), and Dr. Raiany Romanni @RaianyRomanni (@AFARorg / Amaranth) for joining us to share their insights with legislative offices.

Aging Initiative’s first ever Legislative Briefing on Aging Biology at the Massachusetts State House was a massive success!

For everyone who missed FAR 2025, here’s @neurajohn of @untillabs (Series A $58M) breaking down the future of organ preservation. youtu.be/I6kIXVIJOv4

There was no plan to solve aging. When @MartinBJensen arrived at the National Institute on Aging in 2010, he expected a roadmap, a strategy, and a coordinated effort to tackle it. There wasn't one. And 15 years later, the scale of that problem is clearer. The entire longevity field operates with around 2,000 researchers (fewer than what Coinbase or Zoom employ) generating at most half a dozen new medicines ideas each year, with no systematic approach or central coordination to turn aging research into medicine. @MartinBJensen walked through his journey at @aginginit's mixer, from that moment at the NIA to founding @NornGroup, because not having a plan makes it harder to win. The field needs visibility into what’s happening and what’s missing. Norn identifies the constraints, from idea generation to validation speed to coordination, then makes solutions happen.

Thank you to everyone who joined us for our CompBio Speaker Event & Workshop! Special thanks to @mahdi_moqri (HMS), co-director of the @agingbiomarkers , for a behind-the-scenes look at how open-source tools like Biolearn are helping build/validate biological aging clocks

Sign up here! luma.com/bgogzm2m

Workshop on Aging Clinical Trial Design for Functional Decline Learn about and brainstorm pivotal trial design strategies for function-promoting and multimorbidity-targeted therapeutics in aging / age-related functional decline with an interactive workshop.

Sign up here! fs8.formsite.com/GSA1945/5jcg1o… Free for undergrads & grad students

Join us for the Future of Aging Forum, a one-day interdisciplinary conference designed to inspire and equip students to shape the future of aging policy, advocacy, science, and health.

Check out this article by @AgingJrnl covering FAR 2025! aging-us.org/2025/11/aging-…